Impax Laboratories Inc (IPXL.OQ)

IPXL.OQ on NASDAQ Stock Exchange Global Select Market

48.90USD
4:00pm EDT
Change (% chg)

$1.89 (+4.02%)
Prev Close
$47.01
Open
$47.42
Day's High
$49.08
Day's Low
$46.83
Volume
401,017
Avg. Vol
237,368
52-wk High
$52.09
52-wk Low
$22.18

IPXL.OQ

Chart for IPXL.OQ

About

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. The Company operates in two segments: Impax Generics and Impax Specialty... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $3,370.72
Shares Outstanding(Mil.): 71.70
Dividend: --
Yield (%): --

Financials

  IPXL.OQ Industry Sector
P/E (TTM): 74.48 37.18 39.28
EPS (TTM): 0.63 -- --
ROI: 3.72 16.31 15.64
ROE: 5.19 17.08 16.64
Search Stocks

UPDATE 2-Impax's Parkinson's drug gets FDA approval

* Taiwan facility free to commercially manufacture - analyst

08 Jan 2015

Impax's Parkinson's drug gets FDA approval

- Impax Laboratories Inc said the U.S. Food and Drug Administration had approved Rytary, its drug for treating Parkinson's disease, two years after initially rejecting it.

08 Jan 2015

CORRECTED-UPDATE 1-Impax's Parkinson's drug gets FDA approval

(Corrects paragraph 12 to replace "oral" with "injectable liquid" and corrects dateline to Jan. 8 from Jan. 2)

08 Jan 2015

REFILE-Impax's Parkinson's drug gets FDA approval

Jan 8 - Impax Laboratories Inc said the U.S. Food and Drug Administration had approved Rytary, its drug for treating Parkinson's disease.

08 Jan 2015

Fitch: M&A Drives Negative Global Pharma Rating Outlook for 2015; Sector Fundamentals Intact

(The following statement was released by the rating agency) Link to Fitch Ratings' Report: 2015 Outlook: Global Pharmaceuticals (Strategic Industry Evolution to Continue; M&A Reduces Rating Headroom) http://www.fitchratings.com/creditdesk/reports/report_frame.cfm?rpt_id=834168 LONDON, December 11 (Fitch) Fitch Ratings believes 2015 will be a transitional year for global pharma companies as they continue to evolve their business models and position themselves for structural changes in the indu

11 Dec 2014

Earnings vs. Estimates

Search Stocks